1. AMEX compliance announcement. Announcement due at any time.2. Final results of Mayo study for its FDA approved cancer detection test, "Onku-Sure", which confirms its superiority to the industry standard CEA test. Results due out at any time.3. Radient's management announces that its in buyout talks with a company such as J & J or Quest Diagnostics.A number of analysts have $3.00+ price targets on Radient.Due diligence but due check it out.
AMEX compliance meeting was last Thursday. Company now has over $15,000,000 in cash on hand and over $26,000,000 in shareholder's equity.Millions of naked short shares to be covered.